Literature DB >> 20725991

Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes.

Francesca Micci1, Rolf I Skotheim, Lisbeth Haugom, Jörg Weimer, Anne Mette E Eibak, Vera M Abeler, Claes G Trope, Norbert Arnold, Ragnhild A Lothe, Sverre Heim.   

Abstract

Alterations of chromosome 19 are among the most frequent cytogenetic changes in ovarian carcinomas. They usually occur as added extra material of unknown origin to 19p or, less frequently, 19q but sometimes as homogeneously staining regions. The precise nature of these markers, i.e., exactly which regions of chromosome 19 are involved and from which chromosome(s) the additional material comes, could only rarely be established. We have investigated by high resolution array-CGH a series of 29 chromosome 19 markers after previous microdissection of ovarian carcinoma metaphases followed by FISH to determine where in chromosome 19 the rearrangements took place as well as from which partner chromosomes the additional material stems, obtaining informative results on 23 markers from 18 carcinomas. Along the entire chromosome 19, a total of nine regions were found gained in 10 or more carcinomas (from 10 to 16) whereas 15 regions were gained in 6 to 10 markers. The most commonly gained region (16 markers) was observed in 19p13 between 20.80 Mbp and 20.85 Mbp from 19pter. According to the human genome 18 (hg18) NCBI 36, a total of 43 genes reside in the most commonly gained regions. Most of them (n = 31) code for zinc finger proteins. None of these genes is known to be involved in human neoplasia (the only exception is the ZNF91, which is found highly expressed in seminomas) but their frequent gain in the examined tumors makes all of them candidates for a pathogenetic role in ovarian carcinogenesis.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20725991     DOI: 10.1002/gcc.20813

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line-IPO43.

Authors:  Fernanda Silva; Filipa Coelho; Ana Peixoto; Pedro Pinto; Carmo Martins; Ann-Sophie Frombach; Vítor E Santo; Catarina Brito; António Guimarães; Ana Félix
Journal:  Cancer Cell Int       Date:  2022-04-30       Impact factor: 6.429

2.  ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.

Authors:  Lori Rink; Michael F Ochs; Yan Zhou; Margaret von Mehren; Andrew K Godwin
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

3.  Genomic profile of ovarian carcinomas.

Authors:  Francesca Micci; Lisbeth Haugom; Vera M Abeler; Ben Davidson; Claes G Tropé; Sverre Heim
Journal:  BMC Cancer       Date:  2014-05-05       Impact factor: 4.430

4.  Involvement of DPP9 in gene fusions in serous ovarian carcinoma.

Authors:  Marianne Lislerud Smebye; Antonio Agostini; Bjarne Johannessen; Jim Thorsen; Ben Davidson; Claes Göran Tropé; Sverre Heim; Rolf Inge Skotheim; Francesca Micci
Journal:  BMC Cancer       Date:  2017-09-11       Impact factor: 4.430

5.  The plasma peptides of ovarian cancer.

Authors:  Jaimie Dufresne; Pete Bowden; Thanusi Thavarajah; Angelique Florentinus-Mefailoski; Zhuo Zhen Chen; Monika Tucholska; Tenzin Norzin; Margaret Truc Ho; Morla Phan; Nargiz Mohamed; Amir Ravandi; Eric Stanton; Arthur S Slutsky; Claudia C Dos Santos; Alexander Romaschin; John C Marshall; Christina Addison; Shawn Malone; Daren Heyland; Philip Scheltens; Joep Killestein; Charlotte E Teunissen; Eleftherios P Diamandis; K W Michael Siu; John G Marshall
Journal:  Clin Proteomics       Date:  2018-12-21       Impact factor: 3.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.